

Available online on 15.09.2018 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Research Article

SOLUBILITY ENHANCEMENT, FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE TABLET OF ANTIHYPERTENSIVE DRUG TADALAFIL

Sisodiya Mayuri^{1*}, Saudagar Ravindranath²¹Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India²Department of Pharmaceutical Chemistry, R. G. Sapkal College of Pharmacy, Anjaneri, Nashik- 422213, Maharashtra, India

ABSTRACT

The objective of the study was to enhance the solubility and dissolution rate of Tadalafil using hydrophilic carriers such as polyvinyl pyrrolidone K-30 (PVP), Poloxamer 188, Sodium starch glycolate and compatibility study of Tadalafil with different polymers by FTIR. Characterization of solid dispersion-FTIR, DSC and phase solubility analysis was study to improve the oral bioavailability. Formulation and evaluation of immediate release tablets prepare from solubility enhanced Tadalafil. Among the various approaches Solvent evaporation has gained good acceptance in recent years in the industry for enhancing the solubility and dissolution rate of poorly soluble drugs. Poloxamer 188 used as polymer as it is good solubilizing agent. As per the phase solubility studies, a 3² factorial study were used to prepare the immediate release tablet and evaluated for the interactions and *in vitro* drug release. Sodium Starch Glycolate and PVP used as superdisintegrants. The solubility of tadalafil in selected ratios containing tadalafil and Poloxamer 188 solid dispersion prepared by solvent evaporation was determined. From the various ratios 1:0.5 was resulted in a much higher enhancement (9.75folds). Fourier transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) studies conducted, explain overall drug and excipients compatibility. More than 90% of tadalafil was released from IR tablet within 30 min. There is enhancement of the solubility rate if tadalafil by solid dispersion with Poloxamer 188 prepared by solvent evaporation method. The drug was characterized for its organoleptic properties and the results obtained. The compatibility studies of the drug and polymers showed that there was no incompatibility between them. Wet granulation method showed that, the desirable flow properties for the compression into tablets. Tablets were prepared using wet granulation method resulted into simple, cheap, more suitable method for the manufacturing immediate release dosage form.

Keywords: Immediate release tablet, Superdisintegrants, Wet granulation method, Poloxamer 188.

Article Info: Received 23 July, 2018; Review Completed 18 Aug 2018; Accepted 21 Aug 2018; Available online 15 Sep 2018



Cite this article as:

Sisodiya M, Saudagar R, Solubility enhancement, formulation development and evaluation of immediate release tablet of antihypertensive drug tadalafil, Journal of Drug Delivery and Therapeutics. 2018; 8(5):294-302

DOI: <http://dx.doi.org/10.22270/jddt.v8i5.1872>

*Address for Correspondence:

Mayuri Sisodiya, Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

INTRODUCTION

Hypertension or high blood pressure (BP) is a medical condition, in which the BP in the arteries is persistently elevated. BP is the force of blood pushing up against the wall of blood vessels (arteries and veins). Important organs affected are heart leading to heart attack or heart failure, brain leading to stroke, kidney leading to chronic renal failure, eyes leading to bleeding in retina,

loss of vision, and nerve damage¹. WHO rates the hypertension as one of the most important causes of premature death in worldwide. According to the WHO hypertension is a highly prevalent cardiovascular disease. In India, hypertension is the most prevalent chronic disease. The prevalence of hypertension ranges from 20% to 40% in urban adults and 12-17% among rural adults². Oral route is most common route of administration of drug because of its systemic effect,

patient compliance, less expensive to manufacture. Tablet provides high precision dosing. In most of the cases immediate on set of action is required as compare to conventional therapy. To achieve the rapid onset of action and eliminate the drawbacks of conventional therapy immediate release dosage form is now a days popular oral dosage form. Basic approach used in development is the use of superdisintegrants which provide rapid disintegration of tablet after administration³. This research work is concerned with the formulation and evaluation of immediate release tablet of Tadalafil to provide immediate relief from hypertension. A solubility and dissolution are the key parameters for the therapeutic effect of a drug. Solubility is one of the important parameter to achieve desire concentration of drug in systemic circulation for pharmacological response⁴.

More than 92% of the drug listed in U.S. pharmacopoeia which is having low solubility. It is commonly recognized in the pharmaceutical industry that on average more than 40% of newly discovered drug candidates are having poor solubility. Micronization, Nanonization, salt formation, use of surfactants, solid dispersion are the several methods for enhancement of solubility of the drugs^{5,6,7}. Solid dispersion techniques can be used to increase dissolution and absorption of several insoluble drugs^{8,9}. To date, a number of drugs are not showing complete therapeutic effect because of their poor solubility and dissolution, which in turn leads to poor bioavailability of the drug^{10,11}. So, in the modern days, top most importance is given for increasing the dissolution rate of poorly soluble drugs, which enhances their bioavailability. Solid dispersions are one of the most promising strategies to improve the solubility and dissolution rate of poorly water-soluble drugs¹². By reducing the drug particle size to the absolute minimum, and hence, thereby improving drug wettability, bioavailability may can be significantly improved. They are usually presented as amorphous products the term "solid dispersion" has been utilized to describe a family of dosage forms, whereby the drug is dispersed in a biological inert matrix, usually with a view in order to enhancing the oral bioavailability. More specifically, Chiou and Regelman (1971), defined these systems as "the dispersion of one or more active ingredient in an inert matrix at solid-state prepared by the melting (Fusion), solvent or melting solvent method"^{13,14}. Tadalafil is an inhibitor of phosphodiesterase 5 (PDE-5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). PAH is associated with the impaired release of nitric oxide by the vascular endothelium in the pulmonary vasculature. Inhibition of PDE-5 by tadalafil increases the concentrations of cGMP, resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. Tadalafil is a white or almost white powder and it is poorly soluble in water. Since the dissolution rate of the drug from surface is affected by the carrier has an ultimate influence on the dissolution of the dispersed drug. Hence hydrophilic carrier polaxmer188 was used as carriers for converting Tadalafil into solid dispersions in this study.

MATERIAL AND METHOD

Tadalafil was obtained as gift sample from Cipla Pharmaceutical, Ltd, Mumbai. Polaxmer-188 from Glenmark Pharmaceuticals, Sinnar Nashik, methanol from Research-Lab Fine Chem. Industry, Mumbai, PVP and Sodium starch glycolate from Research-Lab Fine Chem. Industry–Mumbai. lactose, microcrystalline cellulose, Magnesium stearate, talc from Research-Lab Fine Chem. Industry–Mumbai.

Preformulation Study of Drug:

Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as an investigation of physical and chemical properties of drug substance, alone and when combined with excipients. The overall objective of preformulation testing is to generate information useful to the formulator in developing stable and bioavailable dosage forms, which can be mass-produced^{15,16}.

Identification Tests

Organoleptic Properties:

The sample of Tadalafil was studied for organoleptic characteristics such as colour, odour and appearance.

Melting Point:

Melting point of Tadalafil was determined by taking a small amount of sample in a capillary tube closed at one end and placed in melting point apparatus. The melting point was noted in triplicate and average value was noted¹⁷.

IR Spectroscopy

The FT-IR spectrum of the obtained sample of drug was compared with the standard FT-IR spectra of the pure drug.

Solubility: The solubility of Tadalafil was checked in different solvents: water, methanol, ethanol, 0.1 N HCl, 0.1 N NaOH, and phosphate buffer 6.9. mL of was added to 10 mg of Tadalafil separately and shaken vigorously for 5 minute and placed in a constant temperature bath for 15minutes¹⁸.

Differential Scanning Calorimetry: Differential Scanning Calorimetry (DSC) was performed using differential scanning calorimeter (SW9.2, Mettler Star) equipped with a computerized data station on pure drug tadalafil to determine the melting point and exothermic and endothermic peaks. An empty standard aluminium pan was used as reference. DSC scans were recorded at heating rate of 10°C/min in the temperature range 30°-300°C and 40 ml/min of nitrogen flow.

Ultraviolet-Visible Spectroscopy: The UV spectrum of Tadalafil was obtained using UV Visible Double Beam Spectrophotometer (V630, Jasco). Accurately weighed 10 mg of the drug was dissolved separately in solvent (methanol) volume was made up to 100mL by the respective solvent to obtain a stock solution of final concentration 100 µg/mL. Aliquot (1mL) of stock solution of Tadalafil was transferred into a series 10mL volumetric flask and volume was made up to the mark with the respective solvent to produce the concentration

range 10 µg/mL. The resultant solution was scanned from 200 to 400 nm and the spectrum was recorded to obtain the value of maximum wavelength. The stock solution of 100µg/mL was used to prepare different dilutions in the range of 2-20µg/mL. The absorbance values for resulting solutions were measured at λ_{max} using respective solvent as blank by UV-visible spectrophotometer¹⁹.

Compatibility Study:

Physicochemical compatibility study: Compatibility study of drug and polymers was done in vials for 1-month at 40°C. The drug to polymer ratio was taken as 1:0.5, 1:1 and 1:2. The vials were daily checked for gas formation, colour change, liquefaction and caking by visual inspection and results were noted down.

Preparation of solid dispersions of Tadalafil: Solid dispersions were prepared by solvent evaporation technique. Physical mixtures of Tadalafil were prepared by mixing Tadalafil and poloxamer188 in sufficient amount of methanol individually in a glass mortar by trituration for 30 minutes.

Table 1: Composition of various Solid dispersion

S.N.	Composition of Drug polymer	Ratios (w/w)
1	Tadalafil: Poloxamer 188	1:0.5
2	Tadalafil: Poloxamer 188	1:1
3	Tadalafil: Poloxamer 188	1:2

Evaluation of prepared Solid Dispersions:

Production yield: The production yield formulation was calculated using the weight of final product after drying with respect to the initial total weight of the drug and carrier used for the preparation of complex.

Drug content:

About 10 mg drug equivalent were weighed accurately and transferred to 100 ml volumetric flask. From this stock solution (100µg/ml), 1 ml was withdrawn and further diluted upto 10 ml with methanol. This solution was used for the assay for drug content by UV spectrophotometer at 284 nm. Concentration of drug in stock solution was calculated by using calibration curve and from which percentage drug content in complex was calculated.

Fourier Transform Infrared Spectroscopy

Compatibility study was carried out by using Fourier transform infrared spectrophotometer. FTIR study was carried on pure drug and solid dispersion (SD). SD was prepared, and samples were stored at 40°C for 1 month. The infrared absorption spectrum of drug and SD of drug was recorded with a KBr disc over the wave number 4000 to 400 cm⁻¹.

Differential Scanning Calorimetry (DSC):

Thermal analysis was performed using a differential scanning calorimeter equipped with a computerized data station. The sample of pure drug and SD of drug was weighed and heated at a scanning rate of 10°C/min between 30°C and 300°C and 40ml/min of nitrogen flow. DSC analysis gives an idea about the interaction of various materials at different temperatures. It also allows detecting possibility degradation of the material.

X ray Diffraction:

For the structural, crystal, and physical state characterization of Tadalafil, X-Ray diffraction studies were performed for pure drug, Tadalafil. XRD study was carried out with Bruker AXS D8 Advance with Vertical, Theta/2 geometry using copper target, a voltage of 40 kv and a current of 35 mA. The scanning was done over 2θ range of 3° to 135°.

Formulation and Development of Tablet of solid dispersion

Method of preparation of Granules: Tadalafil dispersions were taken in mortar and pestle along with suitable diluents and mixed constantly until a dry mix obtained (before mixing both the diluents and dispersions were allowed to pass through # 22 mesh). The binder was dissolved in hot purified water and stirred constantly until the complete PVP goes into solution. Binder solution was added to above dry mix and mixed slowly. Extra water was added till required consistency of mass is obtained and sifted through #22 mesh to obtain granules. Granules were dried in hot air oven and sifted through #24 to obtain uniform sized granules. The sifted granules were taken and blended with Talc and disintegrant for 10 min. Magnesium stearate was sifted and added to above blend and lubricated for 5 mins. The blend was compressed into tablet using punches and suitable dies with a tablet weight of 250 mg.

Table 2: Composition of formulations as per 3² full factorial design

Formulation Code	F1	F2	F3	F4	F5	F6	F7	F8	F9
Ingredient	Mg								
SD	28	28	28	28	28	28	28	28	28
CCS	7.5	10	12.5	7.5	10	12.5	7.5	10	12.5
SSG	5	5	5	12.5	12.5	12.5	20	20	20
PVP	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5
Magnesium Stearate	10	10	10	10	10	10	10	10	10
MCC	50	50	50	50	50	50	50	50	50
Lactose	141	138.5	136	133.5	131	128.5	126	123	121
Talc	1	1	1	1	1	1	1	1	1

Evaluation of Granules: The flow properties of granules (before compression) were characterized in terms of angle of repose, tapped density, bulk density, Carr's index and Hausner's ratio.

Formulation of Tadalafil Tablets: Tablets each containing 20mg of TD were formulated employing TD co-evaporate of polaxmer188 (1:0.5) along with the usual tablet excipients. The formula of TD tablets is given in Table 2. TD tablets were prepared by conventional wet granulation method.

Evaluation of Tablet:

Thickness: The thickness of tablet is important for uniformity of tablet size. The thickness of the tablets was determined using a Digital Vernier Calliper. Three tablets from each batch were used.

Hardness: For each formulation, the hardness of three tablets was checked using the Monsanto hardness tester (LAB- HOSP).

Friability: Friability is the measure of tablet strength. In this test, number of tablets subjected to combined effect of shock abrasion by utilizing a plastic chamber which revolves at a speed of 25rpm, dropping the tablets at a distance of 6 inches in each revolution. A sample of pre-weighed tablets was placed in Roche Friability tester (Kumar Mfg. Ltd.). This was then operated for 100 revolutions. The tablets then de-dusted and reweighed. Permitted friability limit is 1.0%. Tablets were then weighed, and friability values were determined.

Uniformity of weight: Twenty tablets were weighed individually. Average weight was calculated from the total weight of all tablets. The individual weights were compared with the average weight. The percentage difference in the weight variation should be within the acceptable limits ($\pm 5\%$). The percent deviation was calculated using the following formula.

Drug content uniformity: Five tablets were weighed individually and powdered. The powder equivalent to 20 mg of tadalafil was weighed and dissolved in methanol. The volume was made to 100 with methanol. From this stock solution, 10 $\mu\text{g/ml}$ solution was prepared. The drug contents of the resulting solution were calculated from UV absorbance at 284.0 nm.

Disintegration time: The in-vitro disintegration studies were carried out using Tablet Disintegration Test apparatus. One tablet was placed in each of the six tubes of the basket assembly and disk was added to each tube. This assembly was then suspended in one-liter beaker containing water maintained at $37\pm 2^{\circ}\text{C}$. The basket was then moved up and down through a distance of 5 to 6 cm

at a frequency of 28 to 32 cycles per minutes. The time required for complete disintegration of the tablet was recorded. The test was performed for tablets of all type of formulation (F1-F9).

In-Vitro drug release study: An in-vitro drug release studies of the prepared nine formulations of Conventional tablet were conducted for a period of 60 minutes using an eight station USP type 2 apparatus (paddle type). The agitation speed was 50 rpm. Tadalafil tablet were added to 900 ml of 0.1N HCL at $37 \pm 0.5^{\circ}\text{C}$. 5 ml aliquots were withdrawn at time intervals of 5, 10, 15, 20, 25, 30 min and filtered through Whatmans filter paper. An equal volume of fresh dissolution medium was replaced to maintain the volume of dissolution medium. The filtered samples were analysed spectrophotometrically at 284.0 nm. Cumulative percentage of labelled amount of drug released was calculated.

Stability study: The optimized formulation was wrapped in aluminium foil and subjected to $40 \pm 2^{\circ}\text{C}$ temperature and $75 \pm 5\%$ RH in oven for the period of three months. The formulation was analyzed for organoleptic characteristics, thickness, hardness, drug-content, disintegration time, weight variation and dissolution. In any rational design and evaluation of dosage forms for drugs, the stability of the active component is the major criteria in determining their acceptance or rejection. Stability studies were carried out as per ICH Q1A guidelines. During the stability studies, the product is exposed to normal conditions of temperature and humidity. The optimized Tadalafil formulations were subjected for stability studies.

RESULTS AND DISCUSSION

Preformulation Study:

Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as an investigation of physical and chemical properties of drug substance, alone and when combined with excipients. The overall objective of preformulation testing is to generate information useful to the formulator in developing stable and bioavailable dosage forms, which can be mass-produced. Tadalafil is a white or almost white amorphous and odourless powder. Melting point of Tadalafil was found to be 298°C . It is soluble in methanol and 0.1 N HCL and practically insoluble in water.

IR Spectroscopy:

The FT-IR spectrum of the obtained sample of drug was conducted and compare with the standard FT-IR spectra of the pure drug.




Figure 1: FTIR Spectrum of tadalafil

Differential Scanning Calorimetry (DSC):

Differential Scanning Calorimetry (DSC) was performed using differential scanning calorimeter (SW9.2, Mettler Star) equipped with a computerized data station on pure drug tadalafil to determine the

melting point and exothermic and endothermic peaks. An empty standard aluminium pan was used as reference. DSC scans were recorded at heating rate of 10°C/min in the temperature range 30°-300°C and 40 ml/min of nitrogen flow.




Figure 2: DSC of tadalafil

Characterization of prepared SDs

The prepared SD was subjected for solubility study and optimized ratio was evaluated for further characterization.

Solubility Study:

The prepared SD was subjected for solubility studies to evaluate the effect of carrier on the aqueous solubility of TDL were studied and results of phase solubility analysis are shown in Table.3.

Table 3: Result of Phase solubility study

Sr. No	Formulation Code	Drug	Polymer	Ratio	Solubility(mg/ml) ±S.D.	Fold increase Insolubility (Fold)
1.	Drug	TDL	----	----	0.250	1-fold
2.	SD1	TDL	PLX 188	1:0.5	0.567	9.75-fold
3.	SD2	TDL	PLX 188	1:1	0.385	6.10-fold
4.	SD3	TDL	PLX 188	1:2	0.128	3.90-fold

Drug Content Estimation:

The selected ratios were subjected to the determination of drug content. The drug content in the selected ratios was found to be in range of 92 to 98%. Almost negligible loss of drug may have occurred probably because preparation of combinations was confined to the very small area of mortar.

Production Yield:


The production yield of solid dispersion prepared by solvent evaporation method was found to be 86.66%. Any loss in yield can be attributed to the product remaining adhered to the walls of the mortar which could not be retrieved the results of Percentage Yield.

Table 4: Result of Percentage Yield

Sr. No.	Drug	Polymer	Ratio	Percentage Yield
1.	Tadalafil	PLX 188	1:0.5	86.66 %
2.	Tadalafil	PLX 188	1:1	70 %
3.	Tadalafil	PLX 188	1:2	83.3%


IR Spectroscopy:

The FT-IR spectrum of the Solid dispersion was conducted and compare with the standard FT-IR spectra of the pure drug.

**Figure 3: FTIR Spectrum of SD****Differential Scanning Calorimetry (DSC):**

The solid dispersion showed the melting point reduced to 303°C from 254 °C and 60 °C to 49°C and the intensity of the peak in pure drug is reduced. The sharp endothermic peak of pure drug was not observed in solid dispersion, which indicates that the Tadalafil was

molecularly dispersed and in amorphous form. This change indicates that the dehydration of pure drug and change in the particle size giving more amorphous type of the product this may help in cleaving the solubility of drug. These shifting of peaks are due to the above experimental reason but not to interaction.

**Figure 4: DSC of SD**

X-Ray Diffraction of SD:

Diffraction spectra of solid dispersion prepared by solvent evaporation method are presented in Fig. 5 respectively. The XRD of Tadalafil shows sharp peaks indicating that the drug is of crystalline nature. While

that of solid dispersion shows blunt peaks indicating its amorphous nature. This proves the conversion of crystalline form of drug into amorphous form in solid dispersion. Thus, result of XRD support the findings of the DSC study.




Figure 5: XRD of SD

Evaluation of tablets:

Precompressional evaluation

Table 5: Precompressional evaluation

Batch No.	Bulk density (gm/cm ³)	Tapped density (gm/cm ³)	Compressibility index (%)	Hausner's ratio	Angle of repose(θ)
F1	0.399±0.012	0.4545±0.040	13±0.109	1.15±0.06	23.43±0
F2	0.3949±0.017	0.4690±0.003	15±0.1063	1.18±0.06	22.50±0.19
F3	0.3897±0.022	0.4413±0.007	11±0.12	1.13±0.03	23±0.25
F4	0.3949±0.017	0.4690±0.03	15±0.18	1.18±0.02	28.55±0.65
F5	0.4017±0.017	0.4545±0.040	11±1.26	1.13±0.1	25±0.45
F6	0.3949±0.017	0.4413±0.02	10±0.108	1.11±0.09	23.5±0.29
F7	0.3949±0.017	0.4690±0.03	15±0.44	1.18±0.007	29.55±0.60
F8	0.3846±0.001	0.4545±0.001	15±1.3288	1.18±0.01	23.5±0.96
F9	0.4055±0.002	0.4690±0.03	13±0.9825	1.15±0.04	28.5±0.946

The above results predict that, the Carr's index is in range of 10-15% which is considered as Excellent compression property. Angle of repose less than 30° gives excellent flow property to the granules blend. Similarly, bulk density and tapped density value was

found to be less than one. Hence have good flow property. All these results indicate that, the granules blend possess satisfactory flow and compressibility properties.

Post compressional evaluation:

Table 6: Postcompressional evaluation

Batch No.	Thickness (mm)	Hardness (kg/cm ²)	Friability (%)	Weight variation (mg)	Disintegration Time	% CDR
F1	4.47 ± 0.05	3.46 ± 0.09	1.010±0.045	245.65±0.076	1 min 32 sec	85.05
F2	4.47 ± 0.03	2.50 ± 0.08	0.326±0.040	248 ± 0.36	1min 50 sec	79.65
F3	4.50 ± 0.02	3.06 ±0.074	1.063±0.023	248.2 ± 0.47	1 min	89.1
F4	4.34 ± 0.02	2.73 ±0.09	0.531±0.023	248 ± 0.047	1min 45 sec	94.8
F5	4.48 ± 0.03	3.2 ± 0.06	1.291±0.046	249 ± 0.002	54 sec	92.2
F6	4.49 ± 0.01	2.5 ± 0.05	0.326±0.046	248 ± 0.002	35 sec	98.6
F7	4.47 ± 0.06	2.6 ± 0.06	0.266±0.061	249 ± 0.003	1min 20 sec	96.75
F8	4.49 ± 0.03	3.06 ± 0.1	0.279±0.040	248 ± 0.004	45 sec	89.7
F9	4.49 ± 0.02	2.6 ± 0.1	1.476±2.074	249 ± 0.031	57 sec	89.70

All the tablet preparations were evaluated for various physical parameters before proceeding further. Tablet

weights in all batches varied between 245-250 thickness between 4.47-4.50 and tablet hardness between 2.50-

3.46. Thus, all the physical parameters of the manually compressed tablets were quite within control. The percentage friability, as depicted in Table was in the

range of 0.265-1.476 to be well within approved range (<1%) which indicates the tablet had good mechanical resistance.

Dissolution rate study

Table 7: Dissolution data of Tablets of Tadalafil

Time (min)	Formulation Batches								
	F1 (%)	F2 (%)	F3 (%)	F4 (%)	F5 (%)	F6 (%)	F7 (%)	F8 (%)	F9 (%)
5	43.55	37.8	34.05	47.3	35.95	43.55	34.05	39.75	47.3
10	53.05	51.15	39.75	51.15	49.25	53.05	45.45	53.05	53.05
15	66.30	66.3	56.8	64.35	62.55	68.25	54.9	58.9	66.3
20	72.00	73.80	70.15	75.8	69.75	77.60	66.3	72	75.8
25	80.75	77.40	77.40	83.4	89.00	89.10	89.1	80.75	80.75
30	85.05	79.65	89.1	94.8	92.9	98.6	96.75	89.7	89.70




Figure 6: Dissolution Profile of Tablet (F1-F9)

Dissolution Kinetics:

Release kinetics studies

The dissolution kinetics of optimized batch was applied to various dissolution models such as Zero order, First order, Higuchi, Korsmeyer-peppas. The best fitted model gives the highest R² value and least slope value. Thus, zero order model fits best for the dissolution data of the optimized batch as it showed the highest value for R².

Table 8: Drug Release kinetics of optimized batch

S. N.	Models	R ² Value
1	Zero Order	0.9861
2	First Order	0.9539
3	Higuchi	0.9608
4	Korsmeyer-peppas	0.7825




Figure 7: Model Graph for Zero Order Kinetics

CONCLUSION

There is enhancement of the solubility rate if tadalafil by solid dispersion with Poloxamer 188 prepared by solvent evaporation method. The drug was characterized for its organoleptic properties and the results obtained corroborated with literature. The IR spectra and DSC Thermogram also confirmed the drug's identity and purity. The compatibility studies of the drug and

polymers showed that there was no incompatibility between them. Melting point of tadalafil was found to be 298⁰ C which was within the literature range 301-302⁰C. *In-vitro* release was studied using USP dissolution apparatus at a constant temperature of 37 ± 0.5⁰C at RPM 50 for a period of 30 min shows increase

in drug release. Wet granulation method showed that, the desirable flow properties for the compression into tablets. Tablets were prepared using wet granulation method resulted into simple, cheap, more suitable method for the manufacturing immediate release dosage form.

REFERENCES

1. Brunton L, editor. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-hill Medical Publishing Division; 2006: p.813.
2. Walker R. Clinical Pharmacy and Therapeutics. 5th ed. Edinburgh: Elsevier Ltd.; 2012: p.295-6.
3. Jaimini M and Rawat S: A Review on Immediate Release Drug Delivery System, Res. J. Pharm., Biol. Chem. Sci, 2013; 4(2):1721-1730.
4. Brahmkankar D.M, Jaiswal Sunil B. Biopharmaceutics and pharmacokinetics, A treatise. Absorption of drugs. Edn 2, Vallabh Prakashan, Delhi 2009: p.24-27.
5. Desai K.G.H, Kulkarni A.R, Aminabhavi TM: Solubility of Rofecoxib in the presence of methanol, ethanol and sodium lauryl sulfate at (298.15, 303.15 and 308.15) k. Journal of Chem. Eng, 2003; 48(4):942-945.
6. Liu C. and Desai K.G. H: Solubility of Valdecoxib in the presence of Ethanol and Sodium lauryl sulfate at (298.15, 303.15 and 308.15) k. Journal of Chem. Eng. Data, 2004; 49(6):1847-1850.
7. Desai K.G.H. and Park H. J: Solubility studies of Valdecoxib in the presence of carriers, co-solvents and surfactants. Drug Dev Res, 2004; 62(1): 41- 48.
8. Ford JL. The current status of solid dispersions. Pharm Acta Helv, 1986; 61:69-88.
9. Mayersohn M and Gibaldi M, J, Pharm. Sci., 1996; 55:1323.
10. Uekama K, J.Pharm.Soc., 1980; 100:903
11. Ford JL. The current status of solid dispersions. Pharm Acta Helv., 1983; 58:1
12. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification systems, Eur J Pharm Sci, 2006; 29:278-87.
13. Craig DQ. The mechanism of drug release from solid dispersions in water-soluble polymers, Int J Pharm, 2002; 231:131-44.
14. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems, J Pharm Sci, 1971; 60:1281-302.
15. Jain AK, Solubilisation of Indomethacin Using Hydrotropes For Aqueous Injection, Eur J Pharm Biopharm, 2008; 68:701-714.
16. Agrawal S, Pancholi SS, Jain NK, Agrawal GP. Hydrotropic Solubilisation of Nimesulide for Parenteral Administration Int J Pharm, 2004; 274:149-155.
17. <https://www.drugbank.ca/drugs/DB00820>.
18. <https://pubchem.ncbi.nlm.nih.gov/compound/Tadalafil#section=Physical-Description>.
19. Mohammad Yunoos, D. Gowri Sankar, B. Pragati Kumar, UV Spectrophotometric method for the estimation of tadalafil in bulk and tablet dosage form, E-journal of chemistry, 2010: 7(3).

